Computational prediction of nimbanal as potential antagonist of respiratory syndrome coronavirus

The high pathogenic nature of the Middle East Respiratory coronavirus (MER) and the associated high fatality rate demands an urgent attention from researchers. Because there is currently no approved drug for the management of the disease, research efforts have been intensified towards the discovery...

Full description

Saved in:

Bibliographic Details
Published in:	Informatics in medicine unlocked Vol. 24; p. 100617
Main Authors:	Adegbola, Aanuoluwa Eunice, Fadahunsi, Olumide Samuel, Alausa, Abdulahi, Abijo, Ayodeji Zabdiel, Balogun, Toheeb Adewale, Aderibigbe, Taiwo Sarah, Semire, Banjo, Adegbola, Peter Ifeoluwa
Format:	Journal Article
Language:	English
Published:	Elsevier Ltd 2021 The Authors. Published by Elsevier Ltd Elsevier
Subjects:	Dexamethasone Medicinal plants Molecular dynamics Nimbanal Papain like protease Respiratory syndrome coronavirus Medicinal plants Molecular dynamics Dexamethasone Respiratory syndrome coronavirus Papain like protease Nimbanal
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The high pathogenic nature of the Middle East Respiratory coronavirus (MER) and the associated high fatality rate demands an urgent attention from researchers. Because there is currently no approved drug for the management of the disease, research efforts have been intensified towards the discovery of a potent drug for the treatment of the disease. Papain Like protease (PLpro) is one of the key proteins involved in the viral replication. We therefore docked forty-six compounds already characterized from Azadirachta indica, Xylopia aethipica and Allium cepa against MERS-CoV-PLpro. The molecular docking analysis was performed with AutoDock 1.5.6 and compounds which exhibit more negative free energy of binding, and low inhibition constant (Ki) with the protein (MERS-CoV-PLpro) were considered potent. The physicochemical and pharmacokinetic properties of the compounds were predicted using the Swissadme web server. Twenty-two of the compounds showed inhibition potential similar to dexamethasone and remdesvir, which had binding affinity of −6.8 and −6.3 kcal/mol respectively. The binding affinity of the compounds ranged between −3.4 kcal/mol and −7.7 kcal/mol whereas; hydroxychloroquine had a binding affinity of −4.5 kcal/mol. Among all the compounds, nimbanal and verbenone showed drug likeliness, they did not violate the Lipinski rule neither were they inhibitors of drug-metabolizing enzymes. Both nimbanal and verbenone were further post-scored with MM/GBSA and the binding free energy of nimbanal (−25.51 kcal/mol) was comparable to that of dexamethasone (−25.46 kcal/mol). The RMSD, RMSF, torsional angle, and other analysis following simulation further substantiate the efficacy of nimbanal as an effective drug candidate. In conclusion, our study showed that nimbanal is a more promising therapeutic agent and could be a lead for the discovery of a new drug that may be useful in the management of severe respiratory coronavirus syndrome. [Display omitted]
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	2352-9148 2352-9148
DOI:	10.1016/j.imu.2021.100617